Neuroprotection in Glaucoma: NAD+/NADH Redox State as a Potential Biomarker and Therapeutic Target
No Thumbnail Available
Authors
Petriti, Bledi
Williams, Pete A.
Lascaratos, Gerassimos
Chau, Kai-Yin
Garway-Heath, David F.
Check for full-text access
Issue Date
2021
Type
Article
Language
Keywords
Alternative Title
Abstract
Glaucoma is the leading cause of irreversible blindness worldwide. Its prevalence and incidence increase exponentially with age and the level of intraocular pressure (IOP). IOP reduction is currently the only therapeutic modality shown to slow glaucoma progression. However, patients still lose vision despite best treatment, suggesting that other factors confer susceptibility. Several studies indicate that mitochondrial function may underlie both susceptibility and resistance to developing glaucoma. Mitochondria meet high energy demand, in the form of ATP, that is required for the maintenance of optimum retinal ganglion cell (RGC) function. Reduced nicotinamide adenine dinucleotide (NAD
Description
Citation
Publisher
License
Journal
Cells
Volume
10
Issue
6